PARP1 and Familial prostate cancer: The “Guardant360® CDx from Guardant Health to determine EGFR status in NSCLC patients” and the “FoundationOne® Liquid CDx from Foundation medicine for NSCLC, metastatic castrate resistant prostate cancer (mCRPC), ovarian and breast cancer patients before administration of TKI, PIK3CA, or poly (ADP-ribose) polymerase 1 (PARP) inhibitors” are two NGS-based tests that were recently approved by FDA.